GKGellan Alaa Mohamed Kamel

Gellan Alaa Mohamed Kamel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gellan Alaa Mohamed Kamel has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Shaimaa Hussein

    Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Aljouf, Saudi Arabia

    6 shared publications
  • Eman Harahsheh

    2 shared publications
  • Abdou El-Sharkawy

    Anatomy Department, Faculty of Medicine, Al-Azhar University, Cairo 11754, Egypt

    1 shared publication
  • Abrar Gomaa Abd Elfattah Hassan

    Department of Biochemistry and Molecular Biology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt

    1 shared publication
  • Adel R.A. Abd-Allah

    Pharmacology and Toxicology Department, Faculty of Pharmacy (Boys), Al-Azhar University

    1 shared publication
  • Ahmed A. Allam

    Department of Biology, Biotechnology Program, The American Universityin , Cairo, New Cairo, Egypt

    1 shared publication

Latest Publications

  • Advances in AI’s Future in Toxicology: Integrating Computational Prediction and Clinical Translation Through Explainable Artificial Intelligence

    by Gellan Alaa Mohamed Kamel

    Artificial intelligence (AI) and machine learning are increasingly used in toxicological risk assessment to predict chemical toxicity, identify hazardous compounds, and support regulatory decision-making. However, the widespread adoption of these models is limited by their “black-box” nature, which reduces interpretability, transparency, and regulatory confidence. Explainable artificial intelligence (XAI) has emerged as a promising approach to address these challenges by revealing how input features, including chemical structures, exposure levels, and biological pathways, contribute to toxicity predictions. Techniques such as SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) provide interpretable insights into model decision-making and enhance trustworthiness, accountability, and mechanistic understanding. Despite these advances, most XAI applications in toxicology remain at the computational or preclinical stage, with limited clinical and regulatory translation. This review summarizes current AI-based approaches for toxicity prediction, examines the interpretability challenges that hinder their practical implementation, and highlights the emerging role of XAI in bridging the gap between computational prediction and clinical application. Greater standardization, integration of human data, and collaboration among academia, industry, and regulatory agencies will be essential for advancing transparent and clinically actionable toxicology models.

  • Rebamipide attenuates LPS-induced acute lung injury in rats via modulation of macrophage polarization, PDE4B/cAMP/PKA/p-CREB and NF-κB signaling

    by Gellan Alaa Mohamed Kamel, Asmaa S. Elzaitony, Abrar Gomaa Abd Elfattah Hassan, Zahraa Zakarya Abd El-Hafez Mohammad, Amel B. Ibrahim, Asmaa A. Gomaa

    Acute lung injury (ALI) is a severe, potentially fatal condition associated with respiratory failure and high mortality, with limited effective therapeutic options. Rebamipide (REB), a gastroprotective agent with reported antioxidant and anti-inflammatory properties, has not been fully investigated in ALI. This study aimed to evaluate the effects and underlying mechanisms of REB in a lipopolysaccharide (LPS)-induced ALI rat model. Twenty-four Sprague–Dawley rats were randomly divided into four groups: control, REB (100 mg/kg orally for 10 days), LPS (5 mg/kg intraperitoneally on day 10), and REB + LPS (REB pretreatment for 10 days followed by LPS injection on day 10). REB administration attenuated LPS-induced pulmonary oxidative stress and inflammatory responses, as evidenced by reduced pro-inflammatory cytokines and improved antioxidant status. Additionally, REB modulated macrophage polarization markers and downregulated PDE4B expression. These changes were associated with increased cAMP, PKA, and p-CREB levels, along with inhibition of NF-κB p65 activation in lung tissue. In conclusion, REB exerts protective effects against LPS-induced ALI through modulation of inflammatory and oxidative stress pathways involving the PDE4B/cAMP/PKA/p-CREB axis and NF-κB signaling. These findings suggest that REB may represent a promising candidate for further investigation in inflammatory lung disorders. Graphical Abstract Schematic diagram for protective mechanisms of REB against lipopolysaccharide-induced acute lung injury. The alternative text for this image may have been generated using AI.


  • Diacerein mitigates cisplatin-induced testicular toxicity in rats; Role of Nrf2/ HO-1, NF-κB/caspase-3 and NLRP3/ASC/Caspase-1 signaling pathways

    by Gellan Alaa Mohamed Kamel, Shaimaa Hussein

    Cisplatin (CIS) is an effective chemotherapeutic agent; however, its clinical use is limited by serious adverse effects, including testicular toxicity, which is primarily mediated by oxidative stress, inflammation, and cell death pathways. Diacerein (DIA), a slow-acting anti-inflammatory drug, has recently gained attention for its antioxidant and cytoprotective properties. Twenty-four adult male albino rats were randomly allocated into experimental groups and treated with DIA (50 mg/kg, orally) for 14 consecutive days, along with a single intraperitoneal injection of CIS (7 mg/kg) on day 8. At the end of the experimental period, rats were humanely euthanized. Testicular tissues and serum samples were collected for histopathological and biochemical analyses. DIA markedly attenuated CIS-induced testicular damage, as evidenced by improved histological architecture, increased testicular weight, and restored serum testosterone levels. It alleviated oxidative stress by reducing malondialdehyde (MDA) levels and enhancing antioxidant defenses, including superoxide dismutase (SOD), glutathione (GSH), Nrf2, and HO-1 expression. Furthermore, DIA suppressed inflammation via downregulation of NF-κB and pro-inflammatory cytokines (TNF-α and IL-1β). In addition, DIA inhibited CIS-induced pyroptosis by reducing the expression of NLRP3, ASC, and pro-caspase-1. DIA exerts a protective effect against CIS-induced testicular toxicity through its antioxidant, anti-inflammatory, and anti-pyroptotic activities, highlighting its potential as a therapeutic candidate targeting the Nrf2/HO-1, NF-κB, and NLRP3/ASC/caspase-1 signaling pathways.


  • Vinpocetine Mitigates Methotrexate‐Induced Liver Injury in Rats Through Modulating Intercellular Communication

    by Gellan Alaa Mohamed Kamel, Shaimaa Hussein

    Methotrexate (MTX) has been widely implemented in managing several malignancies, inflammatory conditions such as rheumatic arthritis, and autoimmune illnesses. Hepatotoxicity is a significant side effect of MTX, characterized by increased oxidative stress (OS) and inflammation. Vinpocetine (Vinpo) is a prescription medication with a favorable safety profile. It exerts anti‐inflammatory and oxidant implications that might be novel candidates for protecting against MTX‐induced hepatotoxicity. This study investigates the therapeutic impact of Vinpo against MTX‐stimulated liver damage via the nuclear factor erythroid 2‐related factor 2 (Nrf2)/heme oxygenase‐1 (HO‐1) and nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) pathways. Rats are allocated into three groups: (1) the Control (saline); (2) the MTX‐control (20 mg/kg; injected once i.p.), and (3) the Vinpo + MTX groups. Vinpo was administered orally for 7 days, during which MTX was given intraperitoneally once at the end of Day 3. The liver functions, OS markers, inflammatory mediators, Nrf2, HO‐1, NF‐κB, and apoptotic signals were estimated. Vinpo lead to enhancement in superoxide dismutase (SOD) enzyme activity, elevation in glutathione (GSH), and a hindrance in malondialdehyde (MDA). It also enhances Nrf2 and HO‐1, inhibiting NF‐κB (p65) expression and apoptotic markers. Moreover, Vinpo therapy, in conjunction with MTX, restores the normal histological structure of hepatic tissues. Our data suggested that Vinpo exerts a preventive effect against MTX‐induced toxicity through anti‐oxidative, anti‐inflammatory, and apoptotic activities, mediated via Nrf2/HO‐1/Nf‐κB and caspase‐3/Bax/Bcl‐2 pathways.


  • Open Access

    Modulating Multiple Molecular Trajectories by Nutraceuticals and/or Physical Activity in Attention-Deficit/Hyperactivity Disorder (ADHD)-Like Behaviors in Rat Pups

    by Karema Abu-Elfotuh, Gellan Alaa Mohamed Kamel, Mazin A. A. Najm, Ahmed M. E. Hamdan, Mona T. Koullah, Rasha K. E. Fahmy, Heba Abdelnaser Aboelsoud, Manar A. Alghusn, Budor R. Albalawi, Ahmed M. Atwa, et al.

    Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition affecting cognitive and social functions all over childhood. Monosodium glutamate (MSG) is a common food additive associated with ADHD-like symptoms in children. Nutraceuticals, like sesamol (SE) and astaxanthin (AST), or physical activity (PHA) were reported to possess beneficial effects on human health. Meanwhile, still their neuroprotective effect against ADHD has been poorly investigated. This study aimed to investigate the impact of SE, AST and PHA either separately or combined on ADHD-like behaviors induced by MSG in rat pups. Eighty-four male Sprague Dawley rat pups were randomly allocated into seven groups; control, MSG, (PHA + MSG), (SE + MSG), (AST + MSG), (SE + AST + MSG), and (COMB [PHA + SE + AST] + MSG) and treated for eight weeks. MSG-induced ADHD-like behavior was evaluated, via assessing behavioral outcomes; neurotransmitters’ levels; five pathway biomarkers, coupled with histopathological and immunohistochemical studies. Rats exposed to PHA or treated with SE or AST either separately or combined exhibited enhanced attention, locomotor, and cognitive abilities, compared to MSG-intoxicated group. All treatments remarkably improved MSG-induced abnormalities in neurotransmitters’ levels; biochemical markers; along with histological findings, via modulating HMGB1/RAGE/JAK-2/STAT-3, PI3K/AKT/CREB/BDNF, AMPK/SIRT-1 and PERK/CHOP pathways. Nevertheless, the combination of PHA with nutraceuticals (SE and AST) elicited more favorable effects in all measured parameters and histological findings, compared to other treated groups. In conclusion, this study revealed the superiority of the combination of nutraceuticals with PHA, over other standalone treatments, in amelioration of MSG-induced ADHD-like behaviors in rat pups, via fine-tuning of HMGB1/RAGE, PI3K/AKT/CREB/BDNF, AMPK/SIRT-1 and PERK/CHOP pathways. Graphical Abstract


  • Advancement insights in cancer vaccines: mechanisms, types, and clinical applications

    by Gellan Alaa Mohamed Kamel, Rasha A. Attia, Hifaa G. Al-Noman, Lamiaa A. Salama

    Immunotherapy can treat cancer by boosting the immune system to mark and destroy cancer cells. Cancer vaccine is a promising therapeutic strategy in immunotherapy. Cancer vaccines are divided into four groups according to different preparation techniques: cell-based vaccine, virus-based vaccine, peptide-based vaccine, and nucleic acid-based vaccine. Cancer vaccines can be given with traditional treatments or another immunotherapy to give better results and overcome tumor resistance. The cancer vaccine is a promising immunotherapy that could stimulate the immune response to kill cancer cells and create immune surveillance. However, much work is still needed to identify neoantigens, optimize the vaccination platform, and develop combination therapy to improve the efficacy of immunotherapy. This review highlights the mechanism of action of cancer vaccines, the main four groups of cancer vaccines regarding their development, research progress, and clinical applications, and how to assess immune response following cancer vaccination.


  • Open Access

    HBV Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors (BTKIs): a Systematic Review and Meta-Analysis

    by Ahmed Azzam, Heba Khaled, Basem Osama Ashry, Sarah Mohamed Hussein, Manar Osama, Ameer Ahmed, Omar Yousef, Anees Hjazeen, Ahmed A. Allam, Gellan Alaa Mohamed Kamel

    Purpose of Review: Bruton tyrosine kinase inhibitors (BTKIs) are immunosuppressive cancer therapies approved for the treatment of various mature B-cell malignancies. Hepatitis B virus reactivation (HBVr) is a known complication in patients with chronic or past HBV infection undergoing immunosuppressive chemotherapy. The present work aims to establish the correlation between HBVr and patients receiving BTKIs. Recent Findings: This review included 18 studies. The overall incidence of HBVr was found to be 6.6% in patients with past HBV infections who received ibrutinib. Fourteen cases of HBVr were associated with ibrutinib (two occult hepatitis B infections and twelve past HBV infections). One case of HBV past infection was associated with zanubrutinib, and three cases were recorded for acalabrutinib (one chronic HBV and two past HBV). Most incidents occurred in males older than 60 years within the first year after initiating BTKIs. Three reported cases documented HBVr after discontinuing ibrutinib and zanubrutinib. Two deaths caused by HBVr in patients with past HBV infections were recorded (one for each of acalabrutinib and ibrutinib). Remarkably, HBV antiviral treatment normalized liver functions and eliminated serum HBV in most cases. It was reported that false negativity of HBsAg following reactivation occurred in two cases: one case was attributed to HBsAg escape mutations, and the other to the hook effect. Summary: Our findings show that HBVr risk is intermediate in patients with past HBV infections who receive ibrutinib. Universal anti-HBV prophylaxis before initiating ibrutinib may be an option.